Circulating Serum miRNAs as Diagnostic Markers for Colorectal Cancer
| Autor: | Eman Medhat, Salam Eid, Auhood Nassar, Maha Yahia Ismail, Abeer A. Bahnassy, Marwa M. Hussein, Amira Salah El-Din Youssef, Dalia Omran, Reham Mohamed Gabr, Ola S. Ahmed, Faris Q. Alenzi, Mai M. Lotfy, Abdel-Rahman N. Zekri, Nehal Hussein |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Oncology Carcinogenesis Colorectal cancer medicine.medical_treatment lcsh:Medicine Disease Biochemistry Gastroenterology Inflammatory bowel disease Targeted therapy 0302 clinical medicine Medicine and Health Sciences lcsh:Science Multidisciplinary Reverse Transcriptase Polymerase Chain Reaction Middle Aged Nucleic acids 030220 oncology & carcinogenesis Female Colorectal Neoplasms Research Article Adult medicine.medical_specialty Colonic Polyps Gastroenterology and Hepatology 03 medical and health sciences Internal medicine Gastrointestinal Tumors microRNA Biomarkers Tumor Genetics Cancer Detection and Diagnosis medicine Humans Non-coding RNA Colorectal Cancer Biology and life sciences Receiver operating characteristic business.industry lcsh:R Inflammatory Bowel Disease Case-control study Cancers and Neoplasms Inflammatory Bowel Diseases medicine.disease digestive system diseases Fold change Gene regulation MicroRNAs 030104 developmental biology ROC Curve Case-Control Studies RNA lcsh:Q Gene expression business Biomarkers |
| Zdroj: | PLoS ONE PLoS ONE, Vol 11, Iss 5, p e0154130 (2016) |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0154130 |
| Popis: | Aim The study was designed to assess the possibility of using circulating miRNAs (serum miRNAs) as diagnostic biomarkers in colorectal cancer (CRC) and to identify their possibility as candidates for targeted therapy. Methods The study involved two sample sets: 1- a training set which included 90 patients with colorectal related disease (30 with CRC, 18 with inflammatory bowel disease (IBD), 18 with colonic polyps (CP) and 24 with different colonic symptoms but without any colonoscopic abnormality who were enrolled as control group) and 2- a validation set which included 100 CRC patients. Serum miRNAs were extracted from all subjects to assess the expression profiles for the following miRNAs (miR-17, miR-18a, miR-19a, miR-19b, miR-20a, miR-21, miR-146a, miR-223, miR-24, miR-454, miR-183, miR-135a, miR- 135b and miR- 92a) using the custom miScript miRNA PCR-based sybergreen array. The area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic performance of the studied miRNAs for colorectal cancer diagnosis. Results Data analysis of miRNA from the training set showed that; compared to control group, only miR-19b was significantly up-regulated in patients with IBD group (fold change = 5.24, p = 0.016), whereas in patients with colonic polyps, miR-18a was significantly up-regulated (fold change = 3.49, p-value = 0.018). On the other hand, miR-17, miR-19a, miR-20a and miR-223 were significantly up-regulated (fold change = 2.35, 3.07, 2.38 and 10.35; respectively and p-value = 0.02, 0.015, 0.017 and 0.016; respectively in CRC patients. However, the validation set showed that only miR-223 was significantly up-regulated in CRC patients (fold change = 4.06, p-value = 0.04). Conclusion Aberrant miRNA expressions are highly involved in the cascade of colorectal carcinogenesis. We have found that (miR-17, miR-19a, miR-20a and miR-223) could be used as diagnostic biomarkers for CRC. On the other hand, miR-19b and miR-18a could be used as diagnostic biomarkers for CP and IBD respectively. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|